and a subsequent one.

10. The use of claim 9, wherein said medicament is to be administered intravenously on days 1, 4, 7 and 10.

11. The use of any one of claims 1-10, wherein said medicament is a pharmaceutical composition comprising neridronic acid or a salt thereof and pharmaceutically acceptable vehicles for oral, intramuscular, intravenous, intra-articular, transdermal, sub-cutaneous or topical administration.

12. The use of claim 11, wherein the pharmaceutical composition is to be administered intravenously, and comprises sodium neridronate, sodium chloride, citric acid and sodium citrate, or comprises sodium neridronate, sodium chloride, and sodium bicarbonate.

13. The use of claim 11 or 12, wherein the pharmaceutical composition is present as a unit dose comprising 1-10 ml of aqueous solution in a vial or bottle, said unit dose preferably comprising 70-150 mg of neridronic acid or a salt thereof.

14. The use of any one of claims 1-13, comprising a vial or bottle for intravenous administration comprising neridronic acid or a salt thereof.

15. The use of claim 14, wherein the vial or bottle comprises a unit dose of 70-150 mg of neridronic acid or a salt thereof.

16. The use of claim 15, wherein the vial or bottle comprises 100 mg of neridronic acid or comprising a salt thereof in an amount equivalent to 100 mg of neridronic acid.

17. The use of any one of claim 14-16, wherein said salt of neridronic acid is sodium neridronate.

18. The use of claim 6, wherein said medicament is to be administered intramuscularly.

19. The use of claim 18, wherein said medicament is to be administered intramuscularly at a dosage of 10-100 mg, preferably 15-50 mg.

20. The use of claim 19, wherein said salt of neridronic acid is sodium neridronate and said medicament is to be administered intramuscularly at a dosage equivalent to 25 mg of neridronic acid.